Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026BMC Cardiovascular DisordersOpen Access

Olanzapine treatment significantly increases triglycerides, total cholesterol, and LDL-C, while reducing HDL-C, particularly at higher doses.

View Full Paper
Ask AI
Bookmark
Share

Key result

Olanzapine treatment significantly increases triglycerides, total cholesterol, and LDL-C, while reducing HDL-C, particularly at higher doses.

Authors

FZFang ZhouPJParmida JamilianMSMohammad Safargar

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals olanzapine alters lipid profiles in humans, indicating need for monitoring cardiovascular risk.

Key Points

  • The study aims to analyze the effects of olanzapine on lipid profiles, emphasizing the impact of dose and treatment duration.
  • Conducted a meta-analysis of randomized controlled trials
  • Evaluated the effects of olanzapine on triglycerides, total cholesterol, LDL-C, and HDL-C
  • Assessed lipid changes relative to different doses and treatment periods
  • Olanzapine treatment significantly increases triglycerides, total cholesterol, and LDL-C levels
  • HDL-C levels significantly decrease in response to olanzapine, particularly at higher doses
  • Patients with low baseline BMI are more susceptible to rapid lipid profile changes

Cite This Study

Zhou et al. (2026) studied this question. Olanzapine treatment significantly increases triglycerides, total cholesterol, and LDL-C, while reducing HDL-C, particularly at higher doses.

synapsesocial.com/papers/69612fd330ef6c21f6853cdchttps://doi.org/10.1186/s12872-025-05476-z
View Full Paper
Ask AI
Bookmark
Share